-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
What Is The Ownership Structure Like For Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380)?
What Is The Ownership Structure Like For Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380)?
If you want to know who really controls Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.
Joincare Pharmaceutical Group IndustryLtd has a market capitalization of CN¥22b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the company. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Joincare Pharmaceutical Group IndustryLtd.
See our latest analysis for Joincare Pharmaceutical Group IndustryLtd
SHSE:600380 Ownership Breakdown July 17th 2022What Does The Institutional Ownership Tell Us About Joincare Pharmaceutical Group IndustryLtd?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Joincare Pharmaceutical Group IndustryLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Joincare Pharmaceutical Group IndustryLtd's historic earnings and revenue below, but keep in mind there's always more to the story.
SHSE:600380 Earnings and Revenue Growth July 17th 2022Joincare Pharmaceutical Group IndustryLtd is not owned by hedge funds. The company's largest shareholder is Shenzhen Baiyeyuan Investment Co., Ltd., with ownership of 48%. Tencent Holdings Limited is the second largest shareholder owning 3.1% of common stock, and National Council for Social Security Fund holds about 1.6% of the company stock.
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Joincare Pharmaceutical Group IndustryLtd
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own less than 1% of Joincare Pharmaceutical Group Industry Co.,Ltd.. However, it's possible that insiders might have an indirect interest through a more complex structure. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥48m worth of shares. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 42% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
We can see that Private Companies own 48%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Public Company Ownership
It appears to us that public companies own 3.1% of Joincare Pharmaceutical Group IndustryLtd. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Joincare Pharmaceutical Group IndustryLtd is showing 1 warning sign in our investment analysis , you should know about...
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了Joincare制药集团工业有限公司(SHSE:600380),那么你就得看看它的股票登记簿的构成。机构通常持有较成熟公司的股票,而内部人士拥有相当一部分较小公司的情况并不少见。过去属于公众所有的公司往往拥有较低的内部人持股比例。
Joincare制药集团工业有限公司的市值为220亿元人民币,所以它太大了,不能在雷达下飞行。我们预计,机构投资者和散户投资者都将拥有该公司的部分股权。看看我们关于所有权集团的数据(如下所示),似乎是机构投资者买入了该公司的股票。让我们仔细看看不同类型的股东可以告诉我们关于Joincare制药集团IndustryLtd.的信息。
查看我们对Joincare制药集团IndustryLtd.的最新分析
上海证交所:600380所有权明细2022年7月17日机构所有权告诉我们关于Joincare制药集团工业有限公司的什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
Joincare制药集团IndustryLtd已经在股票登记处登记了机构。事实上,他们在该公司拥有可观的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到Joincare制药集团IndustryLtd的历史收益和收入,但请记住,故事总是有更多的内容。
上海证交所:600380收益和收入增长2022年7月17日Joincare制药集团IndustryLtd不为对冲基金所有。公司第一大股东为深圳市百业源投资有限公司,持股48%。腾讯控股控股有限公司是第二大股东,持有3.1%的普通股,全国社会保障基金理事会持有该公司约1.6%的股份。
在进一步挖掘后,我们发现,前两名股东共同控制着公司一半以上的股份,这意味着他们拥有相当大的权力来影响公司的决策。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。分析师对该股的报道不多,但也不多。因此,它有获得更多报道的空间。
Joincare制药集团IndustryLtd.的内部人所有权
公司内部人的定义可能是主观的,而且在不同的司法管辖区之间确实有所不同。我们的数据反映了个别内部人士,至少捕捉到了董事会成员。管理层最终要向董事会负责。然而,经理人担任执行董事会成员并不少见,尤其是如果他们是创始人或首席执行官的话。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
我们的最新数据显示,内部人士持有Joincare制药集团工业有限公司不到1%的股份。然而,内部人士可能会通过更复杂的结构拥有间接利益。它是一家大公司,所以即使是很小的比例权益也可以在董事会和股东之间建立联盟。在这种情况下,内部人士持有价值4800万元的CN股票。可以说,最近的买入和卖出同样重要。你可以点击这里,看看内部人士是在买入还是卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司42%的股份,因此不能轻易忽视。这种规模的所有权虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
私营公司所有权
我们可以看到,私营公司拥有48%的已发行股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
上市公司所有权
在我们看来,上市公司拥有Joincare制药集团工业有限公司3.1%的股份。很难说肯定,但这表明他们的商业利益交织在一起。这可能是一个战略利害关系,因此值得关注这一所有权变化的空间。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。请注意,Joincare制药集团IndustryLtd正在展示在我们的投资分析中出现1个警告信号,你应该知道关于……
但最终这就是未来,而不是过去,这将决定这家企业的所有者将做得多好。因此,我们认为,看看这份免费报告是明智的,它显示了分析师是否预测到了更光明的未来。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧